000095857 001__ 95857
000095857 005__ 20210902121619.0
000095857 0247_ $$2doi$$a10.1089/tmj.2018.0264
000095857 0248_ $$2sideral$$a116426
000095857 037__ $$aART-2020-116426
000095857 041__ $$aeng
000095857 100__ $$aEcharri, A
000095857 245__ $$aThe Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study
000095857 260__ $$c2020
000095857 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095857 5203_ $$aObjectives: Mobile apps are useful tools in e-health and self-management strategies in disease monitoring. We evaluated the Harvey-Bradshaw index (HBI) mobile app self-administered by the patient to see if its results agreed with HBI in-clinic assessed by a physician.
Methods: Patients were enrolled in a 4-month prospective study with clinical assessments at months 1 and 4. Patients completed mobile app HBI and within 48 h, HBI was performed by a physician (gold standard). HBI scores characterized Crohn''s disease (CD) as remission <5 or active >= 5. We determined agreement per item and total HBI score and intraclass correlation coefficients (ICCs). Bland-Altman plot was performed. HBI changes in disease activity from month 1 to month 4 were determined. Results: A total of 219 patients were enrolled. All scheduled assessments (385 pairs of the HBI questionnaire) showed a high percentage of agreement for remission/activity (92.4%, kappa = 0.796), positive predictive value (PPV) for remission of 98.2%, and negative predictive value of 76.7%. High agreement was also found at month 1 (93.15%, kappa = 0.82) and month 4 (91.5%, kappa = 0.75). Bland-Altman plot was more uniform when the HBI mean values were <5 (remission). ICC values were 0.82, 0.897, and 0.879 in all scheduled assessments, 1 and 4 months, respectively.
Conclusions: We found a high percentage of agreement between patients' self-administered mobile app HBI and in-clinic physician assessment to detect CD activity with a remarkably high PPV for remission. The mobile app HBI might allow a strict control of inflammation by remote monitoring and flexible follow-up of CD patients. Reduction of sanitary costs could be possible.
000095857 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/2015–2017
000095857 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095857 590__ $$a3.536$$b2020
000095857 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b36 / 108 = 0.333$$c2020$$dQ2$$eT2
000095857 592__ $$a0.95$$b2020
000095857 593__ $$aHealth Informatics$$c2020$$dQ1
000095857 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000095857 593__ $$aHealth Information Management$$c2020$$dQ1
000095857 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095857 700__ $$aVera, I
000095857 700__ $$aOllero, V
000095857 700__ $$aArajol, C
000095857 700__ $$aRiestra, S
000095857 700__ $$aRobledo, P
000095857 700__ $$aCalvo, M
000095857 700__ $$aGallego, F
000095857 700__ $$aCeballos, D
000095857 700__ $$aCastro, B
000095857 700__ $$aAguas, M
000095857 700__ $$0(orcid)0000-0003-3970-5457$$aGarcía-López, Santiago$$uUniversidad de Zaragoza
000095857 700__ $$aMar?n-Jim?nez, I
000095857 700__ $$aChaparro, M
000095857 700__ $$aMesonero, P
000095857 700__ $$aGuerra, I
000095857 700__ $$aGuardiola, J
000095857 700__ $$aNos, P
000095857 700__ $$aMu?iz, J
000095857 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000095857 773__ $$g26, 1 (2020), 78-86$$pTelemed. J. e-Health$$tTELEMEDICINE AND E-HEALTH$$x1530-5627
000095857 8564_ $$s322355$$uhttps://zaguan.unizar.es/record/95857/files/texto_completo.pdf$$yVersión publicada
000095857 8564_ $$s19911$$uhttps://zaguan.unizar.es/record/95857/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095857 909CO $$ooai:zaguan.unizar.es:95857$$particulos$$pdriver
000095857 951__ $$a2021-09-02-08:46:09
000095857 980__ $$aARTICLE